Clinical Trial Update: NOV-002 in Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 trial of NOV-002 in myelodysplastic syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• NOV-002

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: WITHDRAWN